- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05085223
Prospective Analysis Into Development of Hypernatremia in Critically Ill Patients (HYPNIC II)
Development of Hypernatremia in Critically Ill Patients: Prospective Analysis
Hypernatremia is frequently encountered in patients admitted to the Intensive Care Unit (ICU) and associated with increased mortality and length of stay. Previous studies focused on predictors in the development and recovery of hypernatremia by including amount and types of administered medication, fluid balance, laboratory results and changes in vital signs. However, data of larger populations or data on infusion rates, fluid and sodium balance or renal replacement therapy is lacking. The predecessor of this study was the HYPNIC trial which found that increased sodium load en decreased sodium excretion preceded hypernatremia development, but was lacking information on the first 48 hours, fluid balances were manually collected before a new data collection system was introduced and was suffering from substantial amounts of missing data and small population for trend analysis.
This study aims to provide better insight in the development and recovery of hypernatremia while paying attention to the limitations from the HYPNIC trial.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Eveline Mestrom, MD
- Phone Number: 0031402399500
- Email: eveline.mestrom@catharinaziekenhuis.nl
Study Contact Backup
- Name: Jonna van der Stam, MSc
- Phone Number: 0031402398675
- Email: Jonna.vd.stam@catharinaziekenhuis.nl
Study Locations
-
-
Noord-Brabant
-
Eindhoven, Noord-Brabant, Netherlands, 5623 EJ
- Catharina Hospital Eindhoven
-
Contact:
- Eveline Mestrom, MD
- Phone Number: 0031402399500
- Email: eveline.mestrom@catharinaziekenhuis.nl
-
Contact:
- Ashley de Bie, MD, PhD
- Phone Number: 0031402399500
- Email: ashley.d.bie@catharinaziekenhuis.nl
-
Principal Investigator:
- Jonna van der Stam, M.Sc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Admitted to Intensive Care Unit
- Age 18 years or older
Exclusion Criteria:
- Age 17 years or younger
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hypernatremia
Time Frame: During admission in ICU
|
After one year of collecting data on fluid and sodium balances, the patients who developed hypernatremia during their admission in the Intensive Care Unit will be compared to the patients who remained normonatremic throughout their ICU admission.
|
During admission in ICU
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
24 hour urine replacement for spot-checks
Time Frame: 24 hours
|
Assessing whether 24 hour urine collection can be replaced by spot-check measurements of urine by comparing both 24 hour urine and 2 hourly urine samples
|
24 hours
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HYPNIC II
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.